The Lee group has developed a new point of care rapid test for Chlamydia trachomatis, which has been evaluated in 3 clinical sites in the UK with excellent results in performance characteristics and ease-of-use features. The test recently received regulatory approval for use in the European Union, thus paving the way for it to enter clinical practice. Ongoing work supported by the BRC is includes the development of rapid Simple Amplification-Based Nucleic Acid Testing (SAMBA-NAT) Systems for both HIV and Avian Influenza.
Section:
Immunity and Infection
